Iridex Corporation (NASDAQ:IRIX) Can’t Be More Risky. Short Interest Increased

IRIDEX Corporation (NASDAQ:IRIX) Logo

Investors sentiment decreased to 0.91 in 2019 Q2. Its down 0.09, from 1 in 2019Q1. It is negative, as 4 investors sold IRIDEX Corporation shares while 7 reduced holdings. 2 funds opened positions while 8 raised stakes. 6.67 million shares or 13.57% more from 5.87 million shares in 2019Q1 were reported.
Blackrock Incorporated holds 0% in IRIDEX Corporation (NASDAQ:IRIX) or 82,866 shares. Osborne Capital Management Limited Liability reported 0.03% of its portfolio in IRIDEX Corporation (NASDAQ:IRIX). Eidelman Virant Capital invested in 0.31% or 129,787 shares. Vanguard Gru has invested 0% in IRIDEX Corporation (NASDAQ:IRIX). Lpl Fincl Lc stated it has 0% in IRIDEX Corporation (NASDAQ:IRIX). Moreover, California Employees Retirement System has 0% invested in IRIDEX Corporation (NASDAQ:IRIX) for 32,100 shares. Wasatch Incorporated accumulated 0.06% or 1.31 million shares. Northern Trust invested in 65,483 shares. Stifel Fincl reported 0% in IRIDEX Corporation (NASDAQ:IRIX). 121,803 are held by Essex Investment Mngmt Com Limited Liability Company. Blair William And Il stated it has 43,600 shares or 0% of all its holdings. Acuta Capital Prtn Ltd Liability Co reported 1.17 million shares stake. Bridgeway Mngmt Inc, Texas-based fund reported 81,500 shares. Renaissance Llc holds 385,862 shares. Ingalls Snyder Llc holds 25,015 shares or 0.01% of its portfolio.

The stock of Iridex Corporation (NASDAQ:IRIX) registered an increase of 303.67% in short interest. IRIX’s total short interest was 319,300 shares in September as published by FINRA. Its up 303.67% from 79,100 shares, reported previously. With 24,500 shares average volume, it will take short sellers 13 days to cover their IRIX’s short positions.

The stock decreased 1.73% or $0.04 during the last trading session, reaching $2.27. About 36,532 shares traded or 5.95% up from the average. IRIDEX Corporation (NASDAQ:IRIX) has declined 55.38% since September 13, 2018 and is downtrending. It has underperformed by 55.38% the S&P500.

IRIDEX Corporation provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company has market cap of $31.23 million. The firm offers laser consoles, such as Cyclo G6 laser system used for the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It currently has negative earnings. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physicians to perform multi-spot pattern scanning; Slit Lamp Adapter, which allows the physicians to utilize a standard slit lamp in diagnosis and treatment procedures; and TruFocus laser indirect ophthalmoscopes for use in procedures to treat peripheral retinal disorders.

More notable recent IRIDEX Corporation (NASDAQ:IRIX) news were published by: which released: “IRIDEX Announces Appointment of Maria Sainz and David Bruce to its Board of Directors – GlobeNewswire” on April 16, 2018, also with their article: “Ken Ludlum Appointed to IRIDEX Board of Directors – GlobeNewswire” published on April 02, 2019, published: “IRIDEX Corp (IRIX) CEO David Bruce on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” on August 10, 2019. More interesting news about IRIDEX Corporation (NASDAQ:IRIX) were released by: and their article: “CIBT Subsidiary Takes Possession of GEC Education Mega Center Land – Nasdaq” published on September 03, 2019 as well as‘s news article titled: “IRIDEX Announces Leadership Transition; David Bruce Appointed President and CEO – GlobeNewswire” with publication date: May 21, 2019.

IRIDEX Corporation (NASDAQ:IRIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.